Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate the mutant tumor suppressor protein p53. p53 is the protein expressed from the TP53 gene, the most commonly mutated gene in cancer. Co.'s primary product candidate, APR-246, or eprenetapopt, is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia. Co. is conducting multiple trials in hematologic malignancy indications, including a Phase 3 trial of eprenetapopt with azacitidine for frontline treatment of TP53 mutant MDS. The APRE stock yearly return is shown above.
The yearly return on the APRE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the APRE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|